These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24126833)

  • 1. Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease.
    Hradsky O; Ohem J; Zarubova K; Mitrova K; Durilova M; Kotalova R; Nevoral J; Zemanova I; Dryak P; Bronsky J
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):320-4. PubMed ID: 24126833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.
    Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Angelberger S; Novacek G; Mikulits A; Vogelsang H; Reinisch W
    Eur J Clin Invest; 2011 Oct; 41(10):1071-6. PubMed ID: 21413978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease.
    Schoepfer AM; Flogerzi B; Fallegger S; Schaffer T; Mueller S; Nicod L; Seibold F
    Am J Gastroenterol; 2008 Nov; 103(11):2799-806. PubMed ID: 18684188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.
    Kurti Z; Lovasz BD; Gecse KB; Balint A; Farkas K; Morocza-Szabo A; Gyurcsanyi A; Kristof K; Vegh Z; Gonczi L; Kiss LS; Golovics PA; Lakatos L; Molnar T; Lakatos PL
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):467-72. PubMed ID: 26697573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients.
    Wong SH; Ip M; Tang W; Lin Z; Kee C; Hung E; Lui G; Lee N; Chan FK; Wu JC; Sung JJ; Ng SC
    Inflamm Bowel Dis; 2014 Nov; 20(11):2067-72. PubMed ID: 25159454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease.
    Kaur M; Singapura P; Kalakota N; Cruz G; Shukla R; Ahsan S; Tansel A; Thrift AP; El-Serag HB
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1616-1621.e1. PubMed ID: 29175527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Shahidi N; Fu YT; Qian H; Bressler B
    Inflamm Bowel Dis; 2012 Nov; 18(11):2034-42. PubMed ID: 22294550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy.
    Greveson K; Goodhand J; Capocci S; Woodward S; Murray C; Cropley I; Hamilton M; Lipman M
    J Crohns Colitis; 2013 Jun; 7(5):412-8. PubMed ID: 23009739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-γ release assay for the diagnosis of latent tuberculosis in children younger than 5 years of age.
    Pavić I; Topić RZ; Raos M; Aberle N; Dodig S
    Pediatr Infect Dis J; 2011 Oct; 30(10):866-70. PubMed ID: 21572371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease.
    Arias-Guillén M; Riestra S; de Francisco R; Palacios JJ; Belda J; Escalante P; Pérez-Martínez I; Molinos LM; Garcia-Clemente M; Pando-Sandoval A; Rodrigo L; Prieto A; Martínez-Camblor P; Losada A; Casan P
    Inflamm Bowel Dis; 2014 Feb; 20(2):329-38. PubMed ID: 24378597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Indeterminate Rates Associated With Use of the QuantiFERON-TB Gold In-Tube Test in Children With Inflammatory Bowel Disease on Long-term Infliximab.
    Vortia E; Uko VE; Yen-Lieberman B; Frawley J; Worley SE; Danziger-Isakov L; Kaplan B; Mahajan L
    Inflamm Bowel Dis; 2018 Mar; 24(4):877-882. PubMed ID: 29562270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-gamma release assay for screening of tuberculosis infection in children.
    Zheng H; Xiao J; Li F; Chen H; Li D; Wang Y; Guo Y; Chen Y; Shen C
    BMC Infect Dis; 2023 Dec; 23(1):873. PubMed ID: 38093183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents.
    Machingaidze S; Verver S; Mulenga H; Abrahams DA; Hatherill M; Hanekom W; Hussey GD; Mahomed H
    Am J Respir Crit Care Med; 2012 Nov; 186(10):1051-6. PubMed ID: 22955316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
    Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection.
    Bélard E; Semb S; Ruhwald M; Werlinrud AM; Soborg B; Jensen FK; Thomsen H; Brylov A; Hetland ML; Nordgaard-Lassen I; Ravn P
    Inflamm Bowel Dis; 2011 Nov; 17(11):2340-9. PubMed ID: 21319275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: a single-center retrospective study.
    Theodoropoulos N; Lanternier F; Rassiwala J; McNatt G; Preczewski L; DeMayo E; Stosor V; Ison MG
    Transpl Infect Dis; 2012 Feb; 14(1):1-8. PubMed ID: 21883759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions.
    Kleinert S; Tony HP; Krueger K; Detert J; Mielke F; Rockwitz K; Schwenke R; Burmester GR; Diel R; Feuchtenberger M; Kneitz C
    Ann Rheum Dis; 2012 Nov; 71(11):1791-5. PubMed ID: 22586160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.